Abbreviation of Manufacturers' Names 4/30/02
Total Page：16
File Type：pdf, Size：1020Kb
Load more
Recommended publications
-
312.1.Full.Pdf
Ann Rheum Dis: first published as 10.1136/annrheumdis-2021-eular.1066 on 19 May 2021. Downloaded from 312 Scientific Abstracts Acknowledgements: This study was funded by Novartis Pharma AG. The found many DEGs from baseline with GUS treatment and none with PBO. These authors thank Richard Karpowicz, PhD, of Health Interactions, Inc, for providing included genes related to B-, T-, NK-, and plasma cells (increased by GUS) and medical writing support/editorial support, which was funded by Novartis Pharma- neutrophils, monocytes, eosinophils, and macrophages (decreased by GUS), ceuticals Corporation, East Hanover, NJ, in accordance with Good Publication suggestive of a partial normalization of immune cell composition in whole blood. Practice (GPP3) guidelines (http://www.ismpp.org/gpp3). Conclusion: Using whole transcriptome profiling, we detected DEGs in blood Disclosure of Interests: Gurjit S. Kaeley Consultant of: Novartis Pharmaceuti- samples obtained from PsA pts vs. healthy controls, suggesting a dysregulation cals Corporation, Georg Schett Speakers bureau: AbbVie, Bristol Myers Squibb, of immune cell profiles in PsA. The majority of these disease-associated genes Celgene, Janssen, Eli Lilly, Novartis, and Pfizer, Consultant of: AbbVie, Bristol were modulated by GUS, with directionality toward a normalization of whole Myers Squibb, Celgene, Janssen, Eli Lilly, Novartis, and UCB, Grant/research blood transcriptomic signatures. support from: Bristol Myers Squibb, Celgene, GSK, Eli Lilly, and Novartis, Philip REFERENCES: G Conaghan Consultant of: or Speakers bureau: AbbVie, AstraZeneca, Bristol [1] Deodhar A et al. Lancet. 2020;395:1115. Myers Squibb, Eli Lilly, EMD Serono, Flexion Therapeutics, Galapagos, Gilead, [2] Mease P et al. Lancet. 2020;395:1126. Novartis, and Pfizer, Grant/research support from: UK National Institute for Health Research (NIHR) Leeds Biomedical Research Centre, Dennis McGona- Table 1. -
SEB Fund 1 AR 31122019 Final Post BM
Annual Report SEB Fund 1 Status: 31 December 2019 R.C.S K 49 Notice The sole legally binding basis for the purchase of units of the Fund described in this report is the latest valid Sales Prospectus with its terms of contract. Table of Contents Page Additional Information to the Investors in Germany 2 Organisation 3 General Information 5 Management Report 9 Schedule of Investments: SEB Fund 1 - SEB Asset Selection Fund 10 SEB Fund 1 - SEB Europe Index Fund 14 SEB Fund 1 - SEB Global Fund 24 SEB Fund 1 - SEB Global Chance / Risk Fund 33 SEB Fund 1 - SEB Norway Focus Fund 39 SEB Fund 1 - SEB Sustainability Fund Europe 41 SEB Fund 1 - SEB Sustainability Nordic Fund 46 SEB Fund 1 - SEB US All Cap 48 Combined Statement of Operations 50 Combined Statement of Changes in Net Assets 54 Combined Statement of Net Assets 58 Statistical Information 62 Notes to the Financial Statements 74 Audit Report 81 Risk Disclosure (unaudited) 84 Remuneration Disclosure (unaudited) 86 1 Additional Information to the Investors in Germany As at 31 December 2019 Units in circulation: The following Sub-Funds are publicly approved for distribution in Germany: • SEB Fund 1 - SEB Asset Selection Fund • SEB Fund 1 - SEB Global Fund • SEB Fund 1 - SEB Global Chance / Risk Fund • SEB Fund 1 - SEB Sustainability Fund Europe • SEB Fund 1 - SEB Sustainability Nordic Fund The following Sub-Funds are not distributed in Germany: • SEB Fund 1 - SEB Europe Index Fund • SEB Fund 1 - SEB Norway Focus Fund • SEB Fund 1 - SEB US All Cap The information disclosed above is as at 31 December 2019 and this may change after the year end. -
05/01/02 Louisiana Medicaid Management
APPENDIX C 05/01/02 LOUISIANA MEDICAID MANAGEMENT INFORMATION SYSTEM PAGE 1 DEPT OF HEALTH AND HOSPITALS - BUREAU OF HEALTH SERVICES FINANCING LOUISIANA MEDICAID PHARMACY BENEFITS MANAGEMENT UNIT ONLY THESE COMPANIES PRODUCTS ARE COVERED AND ONLY THOSE DOSAGE FORMS LISTED IN APPENDIX A. MEDICAID DRUG FEDERAL REBATE PARTICIPATING PHARMACEUTICAL COMPANIES LABELER PHARMACEUTICAL COMPANY EFFECTIVE END DATE CODE DATE 00002 ELI LILLY & CO 04/01/91 00003 E.R.SQUIBB & SONS,INC 04/01/91 00004 HOFFMAN-LA ROCHE,INC 04/01/91 00005 LEDERLE LABORATORIES AMERICAN CYANAMID 04/01/91 00006 MERCK SHARP & DOHME 04/01/91 00007 SMITHKLINE BEECHAM CORPORATION 04/01/91 00008 WYETH LABORATORIES 04/01/91 00009 THE UPJOHN COMPANY 04/01/91 00011 BECTON DICKINSON MICROBIOLOGY SYSTEMS 10/01/91 07/01/98 00013 ADRIA LABORATORIES DIV.OF ERBAMONT,INC 04/01/91 00014 G.D.SEARLE & CO 04/01/91 01/01/01 00015 MEAD JOHNSON & COMPANY 04/01/91 00016 KABI PHARMACIA 04/01/91 00021 REED & CARNRICK 10/01/96 01/01/97 00023 ALLERGAN,INC 04/01/91 00024 WINTHROP PHARMACEUTICALS 04/01/91 00025 G.D.SEARLE & CO 04/01/91 00026 MILES INC.,PHARMACEUTICAL DIVISION 04/01/91 00028 GEIGY PHARMACEUTICALS 04/01/91 00029 SMITHKLINE BEECHAM CORPORATION 04/01/91 00031 ROBINS,A.H. 04/01/91 00032 SOLVAY PHARMACEUTICALS 04/01/91 00033 SYNTEX 04/01/91 00034 THE PURDUE FREDERICK COMPANY 04/01/91 00037 CARTER-WALLACE,INC 04/01/91 00038 STUART PHARMACEUTICALS,ICI AMERICAS INC 04/01/91 07/01/01 00039 HOECHST-ROUSSEL PHARMACEUTICALS INC 04/01/91 00043 SANDOZ CONSUMER CORPORATION 04/01/91 00044 KNOLL PHARMACEUTICALS -
Overview of Ftc Antitrust Actions in Pharmaceutical Services and Products
OVERVIEW OF FTC ANTITRUST ACTIONS IN PHARMACEUTICAL SERVICES AND PRODUCTS Health Care Division Bureau of Competition Federal Trade Commission Washington D.C. 20580 Markus H. Meier Assistant Director Bradley S. Albert Deputy Assistant Director Saralisa C. Brau Deputy Assistant Director September 2009 TABLE OF CONTENTS Page I. INTRODUCTION. ........................................................... 1 II. CONDUCT INVOLVING PHARMACEUTICAL SERVICES AND PRODUCTS. 3 A. Monopolization. ...................................................... 3 B. Agreements Not to Compete. ............................................ 8 C. Agreements on Price or Price-Related Terms. 14 D. Agreements to Obstruct Innovative Forms of Health Care Delivery or Financing. 20 E. Illegal Tying and Other Arrangements. .................................... 20 III. PHARMACEUTICAL MERGERS. ........................................... 20 A. Horizontal Mergers Between Direct Competitors. 20 B. Potential Competition Mergers. ......................................... 44 C. Innovation Market Mergers. ............................................ 47 D. Vertical Mergers...................................................... 49 IV. INDUSTRY GUIDANCE STATEMENTS...................................... 50 A. Advisory Opinions. ................................................... 50 B. Citizen Petition to the Food and Drug Administration. 51 V. AMICUS BRIEFS. ......................................................... 51 VI. INDICES. ............................................................ -
Annual Report 2014
ANNUAL REPORT 2014 Dress €99 Blazer €19.99 H&M SPRING 2015 MODERN ESSENTIALS SELECTED BY DAVID BECKHAM SPRING 2015 Shirt €19.99 H&M SPRING 2014 Sweater € 19.95 — H&M ANNUAL REPORT 2014 — Contents H&M IN WORDS AND PICTURES This is H&M 8 CEO letter 10 2014 in brief 12 Our brands 16 Sustainable development 36 Our employees 42 Expansion 46 History 54 H&M IN FIGURES Administration report, including proposed distribution of earnings 60 Group income statement 66 Consolidated statement of comprehensive income 66 Group balance sheet 67 Group changes in equity 68 Group cash flow statement 69 Parent company income statement 70 Parent company statement of comprehensive income 70 Parent company balance sheet 71 Parent company changes in equity 72 Parent company cash flow statement 73 Notes to the financial statements 74 Signing of the annual report 90 Auditor’s report 91 Corporate governance report, including information about the board of directors 92 Auditor’s statement on the corporate governance report 104 Five year summary 106 The H&M share 107 Financial information and contact details 108 H&M’s annual accounts and consolidated accounts for the financial year 2013/14 comprise pages 60–90. — THIS IS H&M — Fashion and quality at the best price H&M is a leading global fashion company with strong values and a clear business concept. H&M has a passion for fashion, a belief in people and a desire to always exceed customers’ expectations – and to do so in a sustainable way. H&M’s busi- ness concept is to offer fashion and quality at the best price. -
Creating the Technology to Connect the World
Nokia Annual Report on Form 20-F 2019 on Form Nokia Annual Report Creating the technology to connect the world Nokia Annual Report on Form 20-F 2019 As filed with the Securities and Exchange Commission on March 5, 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 Commission file number 1-13202 Nokia Corporation (Exact name of Registrant as specified in its charter)) Republic of Finland (Jurisdiction of incorporation) Karaportti 3 FI-02610 Espoo, Finland (Address of principal executive offices) Esa Niinimäki, Deputy Chief Legal Officer, Corporate, Telephone: +358 (0) 10 44 88 000, Facsimile: +358 (0) 10 44 81 002, Karakaari 7, FI 02610 Espoo, Finland (Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person) Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934 (the “Exchange Act”): Title of each class Trading Symbol(s) Name of each exchange on which registered American Depositary Shares NOK New York Stock Exchange Shares New York Stock Exchange(1) (1) Not for trading, but only in connection with the registration of American Depositary Shares representing these shares, pursuant to the requirements of the Securities and Exchange Commission. Securities registered pursuant to Section 12(g) of the Exchange Act: None Securities for which there is a reporting obligation pursuant to Section 15(d) of the Exchange Act: None Indicate the number of outstanding shares of each of the registrant’s classes of capital or common stock as of the close of the period covered by the annual report. -
National Lipid Association Annual Summary of Clinical Lipidology 2016 Disclosures Dr. Harold E. Bays: Dr. Bays Discloses That He
National Lipid Association Annual Summary of Clinical Lipidology 2016 Disclosures Dr. Harold E. Bays: Dr. Bays discloses that he has received research grants from Arena Pharmaceuticals, Boehringer Ingelheim, Cargill Inc., GlaxoSmithKline, Novo Nordisk, Orexigen Therapeutics, Shionogi, Takeda, Stratum Nutrition, California Raisin Board, Esperion, Essentialis, Forest, Gilead Sciences Inc., Given, Hoffman-LaRoche, Home Access, Novartis, Omthera, Pfizer, Trygg Pharmaceuticals, TWI Bio, Xoma, Ardea Inc., High Point Pharmaceuticals LLC, Micropharma Limited, TransTech Pharma Inc., TIMI, Pozen, Regeneron, and Elcelyx. He further discloses that he has received honoraria/research grants from Amarin, Amgen, AstraZeneca, Bristol-Myers Squibb, Catabasis, Daiichi-Sankyo Inc., Eisai, Merck & Co, VIVUS, Zeomedex, and WPU. Dr. Peter H. Jones: Dr. Jones has received consulting or speaker honoraria from Merck and Co., Amgen, and Sanofi-Aventis/Regeneron. Dr. W. Virgil Brown: Dr. Brown is the editor of the Journal of Clinical Lipidology and further discloses that he has received consulting fees/honoraria from Akcea, Esperion, Regeneron, Amgen, Genzyme, Pfizer Inc., Merck and Co, GlaxoSmithKline, Medtelligence, and Vindico. Dr. Terry A. Jacobson: Dr. Jacobson has received consulting fees from Merck and Co., Amarin, Amgen, AstraZeneca, and Regeneron/Sanofi-Aventis. Dr. Karen E. Aspry: Dr. Aspry has no disclosures to report. Dr. Christie M. Ballantyne: Dr. Ballantyne has received research grants from Abbott Diagnostics, Amarin, Amgen, Eli Lilly, Esperion, ISIS Pharmaceuticals, Novartis Pharmaceuticals, Pfizer, Otsuka, Regeneron, Roche Diagnostic, Sanofi-Synthelabo, and Takeda Pharmaceuticals. He has also received consulting fees from Abbott Diagnostics, Amarin, Amgen, AstraZeneca, Eli Lilly, Esperion, Genzyme, ISIS Pharmaceuticals, Matinas BioPharma Inc., Merck and Co., Novartis Pharmaceuticals, Pfizer, Regeneron, Roche, and Sanofi-Synthelabo. -
Executive Profile: Genzyme's CEO on Dark Times, Transition and the Long
June 15th 2015 scripintelligence.com Executive profile: Genzyme’s CEO on dark times, transition and the long view David Meeker, CEO of Sanofi company Genzyme, recently found himself hustling back to Genzyme’s Kendall Square offices from a nearby meeting to talk to Scrip’s editor Eleanor Malone about the challenges and opportunities he has encountered in his varied career. In the first of a two-part series, he discusses his experiences in the company that he joined in 1994, and expounds upon issues faced by the industry as a whole. Eleanor Malone: Genzyme went through some dark times before the Sanofi acquisition with the manufacturing issues that led to shortages of enzyme replacement therapies. What lessons did you draw from those difficulties? David Meeker: You are absolutely correct; they were incredibly painful, dark moments. We failed to deliver on the implicit promise David Meeker addresses employees at of ensuring that patients can access the Genzyme’s HQ following a torch relay connecting the company’s sites near Boston medicines that they need. I think we learned to mark International Rare Diseases Day many lessons. On a very tactical level we learned about the lead time that it takes to bring biologic manufacturing up – we realised it right for the patient, given the limitations Many acquisitions destroy value, and a lot too late that we were not going to be at an we had. We were short of product so we had of the destruction happens when people adequate capacity and by the time we started to focus on how to manage the distribution leave: you have the products but you lose to build, even though it was several years of that product in a way which was most the know-how and the critical talent that ahead of when we ran out of medicine, we equitable. -
Buyback of Own Shares for the Purpose of a Capital Reduction Trading on a Second Trading Line on SIX Swiss Exchange
Buyback of own shares for the purpose of a capital reduction Trading on a second trading line on SIX Swiss Exchange ABB Ltd, Zurich On 25 March 2021, the Board of Directors of ABB Ltd, Affolternstrasse 44, 8050 Zurich ("ABB") decided to repurchase its registered shares for a maximum amount of USD 4.3 billion for the purpose of a capital reduc- tion. The Board of Directors of ABB intends to propose to future Annual General Meetings capital reductions through the cancellation of the registered shares repurchased on the second trading line. By way of illustration only, the repurchase volume of a maximum of USD 4.3 billion, based on the closing price of ABB’s registered shares on 6 April 2021 of CHF 29.25 and a USD/CHF exchange rate of 0.93, corre- sponds to up to 136.7 million registered shares or up to 6.3 % of the current share capital and voting rights of ABB. The share buyback program was exempted from the provisions on public takeover offers provided for in section 6.1 of the Circular no. 1 of the Swiss Takeover Board dated 27 June 2013 (status as of 1 January 2016) and refers to a maximum of 205,314,826 registered shares, equivalent to a maximum of 9.47 % of the share capi- tal currently registered in the commercial register (the share capital currently registered in the commercial regis- ter amounts to CHF 260,177,791.68, divided into 2,168,148,264 registered shares, each with a nominal value of CHF 0.12). -
Dyax Corp. 300 Technology Square Cambridge, MA 02139 617 225-2500
Dyax Corp. 300 Technology Square Cambridge, MA 02139 617 225-2500 www.dyax.com Other Offices Dyax SA, Liege, Belgium ADVANCING NOVEL THERAPEUTIC PRODUCTS Dyax Corp. Annual Report 2003 Corporate Information Dyax Achievements 2003 Dyax Goals 2004 Directors Executive Officers and Stock Listing Henry E. Blair Key Employees Common stock has been traded on the Nasdaq Stock Market Advances in Clinical Development Clinical Development Chairman, President and Henry E. Blair* under the symbol DYAX since our initial public offering in Milestones Chief Executive Officer, Chairman, President and August 14, 2000. DX-88/Hereditary Angioedema Dyax Corp. Chief Executive Officer DX-88/Hereditary Constantine E. Stephen S. Galliker, CPA* The following table gives the quarterly high and low sales G Completed 9-patient Phase II trial, met primary endpoints Angioedema Anagnostopoulos, Ph.D. EVP Finance and prices of our common stock for the last three years. G Genzyme Corporation joined Dyax as joint venture partner Managing General Partner, Administration and G Complete Phase II 2001 2002 2003 G Gateway Associates, LP Chief Financial Officer Completed 3 of 4 dose cohorts in 48-patient Phase II EDEMA1 trial EDEMA1 study High Low High Low High Low G Susan B. Bayh, J.D. Lynn G. Baird, Ph.D.* Initiated Phase II EDEMA2 trial G Periodically observe James W. Fordyce SVP Development First Quarter $20.94 $6.56 $11.38 $3.10 $2.25 $1.52 G Orphan Drug designation granted in U.S. and Europe effects of repeat dosing in Phase II EDEMA2 Managing Partner, Robert C. Ladner, Ph.D. Second Quarter $19.99 $6.81 $ 4.68 $3.20 $4.90 $1.67 Fordyce & Gabrielson, LLC SVP and Chief DX-88/On-Pump Open Heart Surgery (CABG) study Third Quarter $21.24 $6.05 $ 4.20 $1.65 $7.50 $2.58 Mary Ann Gray, Ph.D. -
Dividend and Compensation Payments in Light of Covid-19 Pandemic
DIVIDEND AND COMPENSATION PAYMENTS IN LIGHT OF COVID-19 PANDEMIC Information as of 18 November 2020 Annual General Meeting 2019 dividend Company Index Short-time work Board compensation Executive compensation (2020) (paid 2020) ABB SMI unchanged (26.03.2020) unchanged CHF 0.80 - 10% reduction of board compensation for the duration of the 10% reduction of salary for the duration of the crisis crisis Adecco SMI unchanged (16.04.2020) unchanged CHF 2.50 yes - - Aevis Other unchanged (30.04.2020) cancelled - - - Alcon SMI unchanged (06.05.2020) postponed to 2021 - - - Also Other unchanged (24.03.2020) unchanged CHF 3.25 - - - ams SMIM unchanged (03.06.2020) - - - - APG/SGA Other unchanged (14.05.2020) cancelled (from CHF 11.00) yes - 20% reduction of base salary Aryzta Other postponed to 15.12.2020 postponed yes 30% reduction of fees for 3 months 30% reduction salary reduction for 3 months (15% for wider leadership team) Autoneum Other unchanged (25.03.2020) cancelled yes - 10% reduction of base salary Baloise SMIM unchanged (24.04.2020) unchanged CHF 6.40 - - - Barry Callebaut SMIM unchanged (09.12.2020) - - - - BB Biotech SMIM unchanged (19.03.2020) unchanged CHF 3.40 - - - Bobst Other unchanged (07.04.2020) unchanged CHF 1.50 - - - Bossard Other unchanged (08.04.2020) reduced by 50% to CHF 2.00 4% reduction of compensation 4% salary reduction Bucher Industries SMIM unchanged (24.04.2020) unchanged CHF 8.00 yes (mainly FR and IT) - - BVZ Other unchanged (16.04.2020) reduced to CHF 7.50 - - - Calida Group Other brought forward to cancelled -
ABB Group Strategy Update Presentation 2019
— ABB LTD, FEBRUARY 28, 2019 ABB: shaping a leader focused in digital industries Strategy update and implementation roadmap Ulrich Spiesshofer, CEO and Timo Ihamuotila, CFO — Important notices This presentation includes forward-looking information and statements including statements concerning the outlook for our businesses. These statements are based on current expectations, estimates and projections about the factors that may affect our future performance, including global economic conditions, and the economic conditions of the regions and industries that are major markets for ABB Ltd. These expectations, estimates and projections are generally identifiable by statements containing words such as “expects,” “believes,” “estimates,” “targets,” “plans,” “outlook”, “on track”, “2019 framework” or similar expressions. There are numerous risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from the forward-looking information and statements made in this presentation and which could affect our ability to achieve any or all of our stated targets. The important factors that could cause such differences include, among others: – business risks associated with the volatile global economic environment and political conditions – costs associated with compliance activities – market acceptance of new products and services – changes in governmental regulations and currency exchange rates, and – such other factors as may be discussed from time to time in ABB Ltd’s filings with the U.S. Securities and Exchange Commission, including its Annual Reports on Form 20-F. Although ABB Ltd believes that its expectations reflected in any such forward-looking statement are based upon reasonable assumptions, it can give no assurance that those expectations will be achieved.